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Abstract
Background: The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the targets for neutralizing
antibodies (NAbs). No candidate HIV-1 immunogen has yet induced potent, broadly active NAbs (bNAbs). Part of
the explanation may be that previously tested Env proteins inadequately mimic the functional, native Env complex.
Trimerization and the proteolytic processing of Env precursors into gp120 and gp41 profoundly alter antigenicity,
but soluble cleaved trimers are too unstable to serve as immunogens. By introducing stabilizing mutations (SOSIP), we
constructed soluble, cleaved Env trimers derived from the HIV-1 subtype A isolate BG505 that resemble native Env
spikes on virions both structurally and antigenically.
Results: We used surface plasmon resonance (SPR) to quantify antibody binding to different forms of BG505 Env: the
proteolytically cleaved SOSIP.664 trimers, cleaved gp120-gp41ECTO protomers, and gp120 monomers. Non-NAbs
to the CD4-binding site bound only marginally to the trimers but equally well to gp120-gp41ECTO protomers and
gp120 monomers, whereas the bNAb VRC01, directed to the CD4bs, bound to all three forms. In contrast, bNAbs
to V1V2 glycan-dependent epitopes bound preferentially (PG9 and PG16) or exclusively (PGT145) to trimers. We
also explored the antigenic consequences of three different features of SOSIP.664 gp140 trimers: the engineered
inter-subunit disulfide bond, the trimer-stabilizing I559P change in gp41ECTO, and proteolytic cleavage at the
gp120-gp41ECTO junction. Each of these three features incrementally promoted native-like trimer antigenicity.
We compared Fab and IgG versions of bNAbs and validated a bivalent model of IgG binding. The NAbs showed
widely divergent binding kinetics and degrees of binding to native-like BG505 SOSIP.664. High off-rate constants
and low stoichiometric estimates of NAb binding were associated with large amounts of residual infectivity after
NAb neutralization of the corresponding BG505.T332N pseudovirus.
Conclusions: The antigenicity and structural integrity of cleaved BG505 SOSIP.664 trimers render these proteins
good mimics of functional Env spikes on virions. In contrast, uncleaved gp140s antigenically resemble individual
gp120-gp41ECTO protomers and gp120 monomers, but not native trimers. Although NAb binding to functional trimers
may thus be both necessary and sufficient for neutralization, the kinetics and stoichiometry of the interaction influence
the neutralizing efficacy of individual NAbs.
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The trimeric envelope glycoprotein (Env) spikes sparsely
decorate the surface of infectious HIV-1 virions. Each
trimer consists of three hetero-dimers, in which the
membrane-distal subunit gp120 associates non-covalently
with the transmembrane protein gp41 [1]. When the
primary receptor, CD4, on the target-cell surface is
ligated by Env trimers, a site for co-receptor binding is
induced, allowing Env interactions with CCR5 or CXCR4.
These events trigger conformational rearrangements and
a refolding of Env, which drive the fusion of the viral
and cellular membranes, enabling the viral core, which
contains the genetic material, to enter the cytoplasm.
Because the Env trimer mediates these essential functions
and is exposed on the virion exterior, it is the target for
neutralizing antibodies (NAbs), which prevent infection
by blocking viral entry [2,3]. No HIV-1 vaccine candidate
has yet induced the potent, broadly active NAbs (bNAbs)
that would be required to counter circulating HIV-1
strains, which display exceptional sequence variation
in the env gene. But all of Env is not as variable and
one approach to immunogen design is to create soluble,
recombinant antigenic mimics of the functional Env
trimers with the goal of focusing antibody responses
on conserved neutralization epitopes [4-6].
We and others have described the design, structural
properties, and antigenicity of soluble Env trimers con-
taining gp120 subunits and most of the ecto-domain of
gp41 (gp41ECTO)[ 7 - 1 5 ]( s e eM e t h o d s ) .T h em o s ta d v a n c e d
version of these trimers, based on the subtype A founder
virus BG505, is designated BG505 SOSIP.664 gp140
[16,17]. Three-dimensional structures at near-atomic
scale resolution of this trimer in complex with Fabs of
the PGT122 and PGV04 bNAbs have been obtained,
respectively, by x-ray crystallography and cryo-electron
microscopy (EM) [18,19].
An alternative and predominant approach to making
trimeric Env proteins has been to eliminate the cleavage
site between gp120 and gp41ECTO, yielding uncleaved
gp140s (gp140UNC) [9,10,12,14,15,20]. Attempts have
also been made to improve the properties of gp140UNC
proteins by adding heterologous motifs such as Foldon
and T4 bacteriophage fibritin to the C- terminus of
gp41ECTO [12,15,21]. It is now clear, however, that the
purified fraction with the mass of a trimer from various
uncleaved gp140s contains predominantly aberrant, non-
native structures in which three gp120 subunits dangle
off a central, post-fusion 6-helix bundle formed by the
gp41 part of the gp140UNC protein [22,23].
Our goal is to design Env-based immunogens that most
closely mimic the native form of Env found on the virion
surface, so as to enhance the possibilities of inducing
strong bNAb responses. Such responses emerge in only a
minority of subjects after several years of HIV-1 infection
[24]. In contrast, many anti-Env antibodies that arise
during infection are non-neutralizing and recognize
only non-native forms of Env, probably because they
a r ee l i c i t e db ys h e dg p 1 2 0a n do t h e rn o n - f u n c t i o n a lo r
degraded Env proteins [25]. Even infectious virions harbor
a mixture of functional trimers and non-native forms of
Env, some trimeric, others not [26,27]. Among primary
HIV-1 isolates, neutralization correlates poorly with
antibody binding to monomeric gp120 but agrees well
with binding to native trimers [28,29]. The explanation is
that many epitopes on the trimers of primary isolates
are shielded by Env trimerization and intra- and inter-
protomer interactions involving the gp120 variable loops
and glycans [18,19,30-32]. Hence, Env trimers with the
highest ratio of NAb over non-NAb binding might have
desirable immunogenic properties that could be further
improved through knowledge of how bNAbs emerge
during infection.
The BG505 SOSIP.664 gp140 trimers are good anti-
genic mimics of native Env spikes in that they occlude
most non-NAb epitopes but display trimer-dependent and
other bNAb epitopes well [17]. Those antigenic properties
are contingent upon cleavage between the gp120 and
gp41ECTO subunits [23,33-35]. Here, we characterize
the antigenicity of BG505 SOSIP.664 trimers by surface
plasmon resonance (SPR), showing that different bNAbs
bind with widely divergent kinetics. We also compare
bNAb and non-NAb binding to the trimer, the previously
never studied gp120-gp41ECTO protomer (see Additional
file 1: Figure S1), and the gp120 monomer; we dissect how
the cleavage-enhancing and trimer-stabilizing features affect
the antigenicity of the trimers; and we explore binding
differences between monovalent Fabs and bivalent IgG.
We compare these findings with the thermodynamics
of bNAb binding analyzed by isothermal calorimetry
(ITC) and with the high-resolution EM and x-ray crystal-
lographic structures of Fab-trimer complexes [18,19]. We
found a good agreement between the stoichiometries of
Fab binding per trimer determined by other methods and
the estimates derived from SPR data. We suggest that
stoichiometry together with the off-rate constant of
NAb binding influences the efficacy of neutralization.
Results and discussion
Effects of oligomerization on the antigenicity of Env trimers
We compared antibody binding to the BG505 SOSIP.664
trimer, the corresponding disulfide-stabilized gp120-gp
41ECTO protomer, which has previously never been in-
cluded in NAb binding studies, and the gp120 monomer
(see Methods and Additional file 1: Figure S1 for a
description of the protomer). All three antigens were
captured onto SPR chips at levels corresponding to
approximately the same amount of immobilized gp120
(see Methods for different approaches to immobilization
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Table S1 for analyses of the reproducibility of capture
levels). The CD4bs-directed bNAbVRC01, which potently
neutralizes the corresponding BG505.T332N pseudovirus,
bound strongly and similarly to all three antigens, with
markedly slow dissociation. In contrast, the non-NAb b6
and the bNAb b12, also directed to the CD4bs but
which do not neutralize the BG505.T332N pseudovirus
[17], bound well and indistinguishably to the gp120-
gp41ECTO protomer and gp120 monomer, but negligibly
to the trimer (Figure 1). Thus, the lack of neutralization
is due to the trimerization-dependent shielding of epitopes
on the gp120 subunits. The binding kinetics, however,
differed between these two antibodies in that b12 disso-
ciated markedly faster. The non-NAb F240 reacted with
neither trimer nor protomer, which was as expected since
its gp41ECTO epitope is located in cluster I, a region inter-
acting with gp120. Monomeric gp120 served as a negative
control for F240 binding. (That the requisite gp41 se-
quence is present is shown later with uncleaved Env
constructs).
The 2G12 bNAb bound similarly to its glycan-
dependent outer-domain epitope on the gp120 mono-
mer and trimer, and marginally better to the protomer.
The two glycan- and V3-base-dependent bNAbs
PGT123 and PGT128 recognized the trimer somewhat
better than protomer and gp120, with faster dissociation
from the latter two.
The two V3-specific MAbs 14e and 19b, which do not
neutralize BG505.T332N pseudovirus [17], bound
strongly to the gp120 monomer but only negligibly to
the trimer. Plausible mechanisms of the shielding of V3
epitopes include burial of V3 in the trimer interface and
masking by V1V2 [18,19]. Unexpectedly, both MAbs
reacted with the gp120-gp41ECTO protomer substantially
less well than with the gp120 monomer (although better
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Figure 1 The effect of oligomerization on Env antigenicity. The sensorgrams show the binding (RU) of the listed IgGs to the BG505 SOSIP.664
trimer, gp120-gp41ECTO protomer (gp140), and monomeric gp120 over time (s) on the x axis. Association was followed for 5 min and dissociation
for 10 min. The Env proteins were captured on the chip by amine-coupled D7324 antibody. For each Ab tested similar levels of Env were captured:
RL values were~500 RU for trimers and protomers for all Abs except for the V3-specific ones, where RL was ~200 RU for trimer and protomer, and in
all cases ~15% lower for gp120 to yield approximately equal numbers of gp120 subunits for all three forms of Env. The antibodies tested as analytes
bind to different clusters of epitopes: b12, b6, and VRC01 to the CD4bs; F240 to cluster I in gp41; PG9, PG16, and PGT145 to V1V2-glycan epitopes at
the apex of the trimer; PGT151 to a newly discovered epitope that spans the interface between gp120 and gp41ECTO in one protomer and also makes
contact with a second gp41ECTO subunit; 2G12 to a mannose-glycan-dependent epitope; PGT123 and PGT128 to composite V3-base and glycan
epitopes; and 14e and 19b to V3 epitopes. MAbs b12, b6, F240, 14e, and 19b do not neutralize the corresponding BG505.T332N virus, whereas
VRC01, 2G12, PGT123, PGT128, PG9, PG16, PGT145, and PGT151 do. All MAbs were injected at 1 μM. The sensorgrams show one of two replicates.
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therefore seem to contribute, through intra-protomeric
conformational effects, to the nearly complete shielding
of these V3 epitopes on the SOSIP.664 trimer immobilized
on the SPR chip. There are precedents for antigenic effects
of gp41 on gp120 epitopes. For example, a neutralization-
escape mutation in cluster I reduces the sensitivity of the
T-cell line-adapted virus HxB2 to CD4bs-directed Abs
[36-38]; conversely, cluster-I mutations in primary isolates
can confer or contribute to sensitivity to neutralization by
sCD4, b12, or plasma from HIV-1-infected people [39,40].
Furthermore, substitutions in the MPER can strongly
affect viral sensitivity to V3 NAbs [41,42].
To investigate the effect of gp41ECTO on V3 antigenicity,
we used untagged gp120-gp41ECTO protomer and gp120
monomer as analytes and compared their binding to
anti-Fc-immobilized MAbs 14e and 19b. In that format,
the anti-V3 MAbs did not distinguish quite as clearly
between the gp120 monomer and gp120-gp41ECTO pro-
tomer (Additional file 1: Figure S2). Therefore, one
explanation for the lower binding of the V3 MAbs to
the gp120-gp41ECTO protomer than to gp120 monomers,
under the conditions of Figure 1, might be that immobi-
lized protomer molecules interact with each other and
shield the 14e and 19b epitopes [18,19]. The D7324
epitope-tag or the immobilization might also indirectly
affect the exposure or conformation of V3. We also note
that the extent of 14e and 19b binding to the BG505
SOSIP.664 trimer is assay-dependent: the V3 region is
more accessible in a D7324-capture ELISA than in SPR or
electron microscopy [17]. Overall, there is still much to be
learned about what determines the degree of V3 exposure
on different forms of Env and how those factors affect
immunogenicity.
We confirmed that the bNAbs PG9, PG16, and PGT145,
directed to V1V2 quaternary-dependent epitopes, bind
better to the trimer than to the gp120 monomer
[16,43,44]. PG16 dissociated faster from the trimer than
PG9 and PGT145 (Figure 1). While PG9 and PG16 did
react to an extent with gp120 and the gp120-gp41ECTO
protomer, PGT145 bound to neither of those, only to
the trimer. PG9 is known to bind to some gp120 mono-
mers, particularly to BG505 gp120 [45]. Here, PG9 bound
indistinguishably to gp120 and the gp120-gp41ECTO pro-
tomer, although much more weakly than to the trimer.
Hence, the presence of gp41ECTO enhances reactivity
with PG9, PG16, and PGT145, not by affecting the con-
formation of individual gp120 subunits independently
of the trimeric context, but by mediating trimerization
and thus creating the complete epitope described for
this group of bNAbs [16].
The recently described bNAb PGT151, directed to a
novel epitope at the gp120-gp41 interface [46,47], had a
different binding profile. It failed to bind gp120 but did
react with the gp120-gp41ECTO protomer, although less well
than with the trimer (Figure 1). This reactivity profile is
consistent with the demarcation of the PGT151 epitope,
which involves both gp120 and gp41ECTO components of
one protomer and also a second gp41ECTO subunit [46,47].
In summary, whereas trimerization shields non-NAb
epitopes, it is necessary for creating, or optimizing, the
epitopes for several bNAbs. Thus, all non-NAbs bound
well to monomeric forms of Env but not to the trimer,
while the trimer-specific bNAbs exhibited the inverse
pattern. The gp41ECTO moiety within each protomer did
not influence the antigenicity of most gp120 epitopes,
including the CD4bs, but it reduced binding somewhat
to the V3 region on the gp120-gp41ECTO protomers.
Effects of proteolytic cleavage and stabilizing mutations
on antibody binding to Env trimers
Recently, we showed that cleavage at the junction between
gp120 and gp41ECTO strongly promotes a native-like
structure of the BG505 SOSIP.664 gp140 trimer, as de-
termined by negative-stain EM, and that the compact,
native-like trimer binds NAbs but not non-NAbs [23].
Likewise, other biophysical techniques reveal the non-
native structure of uncleaved oligomeric gp140s [22].
The preferential binding of NAbs to proteolytically
processed Env on the cell surface is also well-described
[34]. Here, we extend those observations by further dis-
secting what modifications of BG505 SOSIP.664 Env are
responsible for which antigenic effects.
We studied the binding of nine MAbs to six forms of
Env: SOSIP.R6 (i.e., SOSIP.664) is the fully cleaved and
stabilized form; WT.SEKS lacks both the SOSIP muta-
tions and the cleavage site; SOSIP.SEKS lacks only the
cleavage site; SOS.R6 lacks only the I559P mutation;
SOS.SEKS lacks the I559P mutation and the cleavage
site; IP.SEKS lacks the SOS link between gp120 and
gp41ECTO as well as the cleavage site (Figure 2). Note
that cleaved Env lacking the SOS linkage could not be
studied because with that construct gp120 completely
dissociates from gp41ECTO.
VRC01, a CD4bs bNAb that does neutralize the BG505.
T332N pseudovirus, bound significantly to all six forms of
Env (Figure 2), while clearly differentiating among them.
The weakest binding, while still substantial, occurred with
the most stabilized, native-like form of Env, SOSIP.R6.
Eliminating only the cleavage site (SOSIP.SEKS)m a r -
ginally increased binding, whereas reverting the SOS
mutations and removing the cleavage site (IP.SEKS)
increased binding further. The three highest binding
curves were recorded for SOS.R6, WT.SEKS,a n dSOS.
SEKS, with small increments in that order. Overall, the
more compact trimer structure that is contingent on
cleavage is compatible with binding, while posing a
limited impediment.
Yasmeen et al. Retrovirology 2014, 11:41 Page 4 of 17
http://www.retrovirology.com/content/11/1/41Three MAbs (the CD4bs-specific b6, b12, and the
gp41-directed F240) that do not neutralize BG505 had
distinct sensitivities to Env modifications. All three
MAbs strongly bound to WT.SEKS, although b12 disso-
ciated faster than b6 and F240; none of them bound to
SOSIP.R6, the trimer with the most native-like structure;
and b6 and b12 bound at intermediate levels to SOSIP.
SEKS. The latter result shows that, even in the absence
of cleavage, the trimer-stabilizing modifications partially
mask these overlapping epitopes. The I559P mutation
had a weak but definite masking effect on both the b6
and b12 epitopes when Env was uncleaved (IP.SEKS vs.
WT.SEKS). The SOS modification had a stronger mask-
ing effect for b12 than b6 on uncleaved Env (SOS.SEKS
vs. WT.SEKS). Furthermore, in the cleaved SOS context,
absence of the I559P modification had differential effects
on b6 and b12 binding: b6 bound to SOS.R6 more
strongly than b12 (SOS.R6 vs. SOSIP.R6). Hence, the
I559P point substitution in gp41ECTO influences the
CD4bs. It can be noted that although neither b6 nor b12
neutralizes the BG505.T332N pseudovirus, they have
drastically different properties and modes of Env inter-
action in that b6 is a non-NAb and b12 a bNAb. It is
therefore significant that these two epitopes, overlapping
the CD4bs, are differentially affected by how gp120 is
anchored to gp41ECTO, and also by the presence of the
trimer-stabilizing I559P change.
None of the Env variants containing the SOS modifi-
cation bound the F240 non-NAb against an epitope in
cluster I of gp41ECTO. Either gp120, when disulfide-linked
to gp41ECTO, masks the F240 epitope, or the disulfide
bond to C605 (or just the Cys side chain itself), disrupts
the epitope. The I559P change in the gp140UNC context
enhanced F240 binding (IP.SEKS compared with WT.
SEKS, which differ only at residue-559, Figure 2). The
I 5 5 9 Pc h a n g ep r o b a b l yi m p e d e st h ef o r m a t i o no fas i x -
helix bundle and thereby favors F240 binding.
The binding of 2G12 to the different forms of Env was
similar, which shows that its gp120 epitope is affected by
neither cleavage nor the SOSIP modifications (since all
Env variants were captured to near-identical levels as
shown by the RL values in Additional file 2: Table S1).
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Figure 2 The effects of cleavage and trimer-stabilizing mutations on Env antigenicity. The sensorgrams show the binding (RU) of the listed
MAbs to BG505 SOSIP.664 trimers (labeled “SOSIP.R6”) and five mutated variants thereof (see Results). MAbs b12, b6, F240, 14e, and 19b do not
neutralize the corresponding BG505.T332N virus, whereas VRC01, 2G12, PG16, and PGT145 all do. The SPR method was the same as for Figure 1,
except that the MAbs were injected at 500 nM. The sensorgrams show one of two replicates.
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weakly (<50 RU) to the native-like SOSIP.R6 trimers.
They both bound to intermediate levels with SOS.R6
and SOSIP.SEKS, indicating that the omission of the
I559P change and the lack of cleavage equally increased
exposure of the V3 region. The two V3 MAbs bound to
high and similar levels to WT.SEKS and IP.SEKS, but
yielded even higher levels with SOS.SEKS. When added
to WT.SEKS, I559P alone had no effect, but added to
SOS.SEKS it reduced binding markedly. In summary, the
I559P change in the cleaved context and cleavage itself
both markedly shield V3 epitopes, whereas in the
uncleaved context SOS must be combined with the
I559P change to exert a V3 masking effect. Note that
the reduced binding of these MAbs to the gp120-
gp41ECTO protomer, compared with gp120, also indicated
that gp41ECTO exerts indirect effects on V3 antigenicity
(Figure 1). Overall, however, the Env form that least
exposes V3 non-NAb epitopes is the cleaved, native-like
trimer SOSIP.R6 (elsewhere referred to as SOSIP.664).
Two quaternary structure-dependent bNAbs, PG16
and PGT145, were also studied. PG16 bound strongly
only to SOSIP.R6. It did not recognize the WT.SEKS
uncleaved gp140, but bound to intermediate levels when
the SOSIP modifications were present in the uncleaved
gp140, SOSIP.SEKS. Both IP.SEKS and SOS.R6, which
share no modifications, bound PG16 to low levels. The
I559P change therefore strongly promotes PG16 binding
only when Env is cleaved. For PGT145, the differences
between the strong, high-level binding to the native-like
SOSIP.R6 trimers and the other Env variants were even
starker than for PG16. Thus, PGT145 bound partly to
SOSIP.SEKS, but negligibly to the other variants. In sum-
mary, for full PGT145 binding, cleavage, SOS, and
1559P are all necessary. The PGT145 reactivities with
the different Env variants are strikingly congruent with
the estimated proportions of native-like trimers present,
as determined by negative stain-EM. Thus, apart from
SOSIP.R6, which yields close to 100% native-like trimers,
only the SOSIP.SEKS construct yields more than a few
percent of native-like trimers [23]. Hence the antigenicity
of SOSIP.SEKS reflects its mixed population of native-like
trimers and structurally aberrant forms of Env [23].
Kinetic modeling of and stoichimetric estimates of
monovalent and bivalent binding to Env
There are advantages to studying both monovalent Fabs
and bivalent IgG. The latter is the natural antibody form,
and therefore of greater relevance to blocking viral entry
in vivo. But the degree of bivalent binding to Env trimers
on the virion is uncertain, and it has been argued that
HIV incorporates exceedingly few Env spikes, thereby
disfavoring bivalent NAb binding [48]. Such an escape
strategy could, however, be a double-edged sword. On
the one hand, by having few trimers on its surface, and
hence long average distances between them, HIV-1 would
minimize the enhancement of neutralization potency
that NAb avidity confers [48,49]. On the other hand, an
opposing effect would arise, namely that the fewer
spare trimers virions have, above what is necessary for
infection, the lower would be the minimal occupancy
required for neutralization, an effect making the virus
more vulnerable [50-54].
The spacing and orientation of the epitopes studied
here preclude the bridging of two epitopes on the same
trimer by one IgG molecule, i.e. intra-trimeric bivalent
binding; and for the NAbs PG9, PG16, and PGT145,
directed to the trimer apex, the unusual stoichiometry of
one paratope per trimer already excludes their intra-
trimeric bivalent binding [16,18]. Whether an IgG of any
specificity can bridge two epitopes on the same trimer is
doubtful [48]. The PGT122 Fab binds with an angle that
is incompatible with intra-trimeric cross-linking of epi-
topes by the corresponding IgG. Still, its angle of binding
is deemed less unfavorable for intra-trimeric bivalent
binding than that of any other Fabs studied [18]. Thus,
even for NAbs that, unlike PG9, PG16, and PGT145, can
potentially occupy three epitopes per trimer, only inter-
trimeric bivalent binding needs to be considered.
We do not know how many functional or defective tri-
mers the average infectious virion or pseudovirion carries.
That number is likely to vary over the virion population
and the proportion of functional trimers will decline as
the virions decay. A cryo-EM study of the T-cell line-
adapted isolate MN, however, observed a range of 4 to 35
Env spikes per virion, with an average of 14 [55]. The
range may stretch higher for primary isolates, and virions
with the fewest spikes may not be infectious. Furthermore,
the most frequent nearest-neighbor spacing of spikes
was ~15 nm, and the spikes were not randomly distrib-
uted over the virion surface but tended to cluster.
Therefore, the maximum distance from paratope to
paratope of an IgG molecule would sometimes suffice
for spanning adjacent spikes. For comparison, the density
of Env we used on the chips in standard experiments
was~700 trimer molecules per μm
2, which corresponds
to a density between the average of 14 and the top value
of 35 per virion (see SI for calculations). Hence, although
the different kinds of Env immobilization for SPR used
here differ qualitatively from each other from how trimers
decorate the virion surface (see SI), they are quantitatively
relevant to neutralization. We therefore considered it
worthwhile to explore mixed bivalent-monovalent binding
models by SPR, and assess how closely the monovalent
binding by IgG resembles the binding by Fabs.
We found that the bivalent model identifies a genuine
strengthening of binding by the IgGs due to two-point
binding. Five lines of evidence indicate this: Fab and IgG
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and bivalent models, the relative significances of the
kinetic parameter values, the influence of ligand density,
and the analyte-concentration dependence of the size of
the bivalent component (Additional file 3: Tables S2 and
S3, Additional file 1: Figures S3, S4, S5). Unfortunately,
no comparison with other methods for further validation
of bivalent binding to similarly immobilized Env proteins
is readily available. We can nevertheless conclude that
both monovalent and bivalent binding can be measured
by SPR, although some questions remain about how
accurately the bivalent model attributes the avidity effect
to the second binding event.
The Sm value obtained by SPR is a stoichiometric esti-
mate that primarily serves the purpose of quality control
of the ligand; if only a small fraction of immobilized
trimers were able to bind NAbs, it would indicate that
the trimers were structurally compromised before or after
immobilization. We obtained reassuringly high stoichio-
metric estimates (Additional file 3: Table S4), indicating
that the majorities of the Env molecules (trimers and
protomers) were structurally intact. In addition we found
generally good agreement between the Sm values and the
stoichiometries observed by ITC and EM. For several rea-
sons (see the SI), however, the accuracy and precision of
Sm values can be questioned. We therefore compared
three methods of assessing the stoichiometry and found
that the measurements were quite robust (Additional
file 3: Table S4). Furthermore, the convergence of Sm
estimates for Fabs and IgGs directed to the same epitope
validates the bivalent modeling. We conclude that SPR
can measure bivalent binding and yield reasonable Sm
estimates, which complement the stoichiometric mea-
surements obtained by other methods.
Kinetic differentiation of NAb binding to SOSIP.664 trimers
and gp120-gp41ECTO protomers
The kinetic profiles of VRC01 and PGT122, two NAbs
that bound well to both SOSIP.664 trimers and gp120-
gp41ECTO protomers, are displayed in Figure 3. (As shown
in Figure 1, VRC01 only marginally differentiated among
trimer, protomer, and gp120 in single-concentration quali-
tative analysis, whereas two NAbs, PGT123 and PGT128,
closely related to PGT122, showed a slight trimer prefer-
ence). The comparison by full kinetic modeling revealed
differences in how VRC01 and PGT122 bind to the two
forms of Env. VRC01 bound to the SOSIP.664 trimers
with moderately fast association and markedly slow
dissociation; but as it both associated faster with and
dissociated more slowly from the protomer, its affinity
was 10-fold higher for the protomer than the trimer
(Additional file 3: Table S5). This affinity difference
between trimer and protomer is in line with the results
in Figure 2, which suggests that the formation of stable,
native-like trimers disfavors VRC01 binding. The affin-
ity difference is explained mechanistically by the three-
dimensional cryo-EM structure of the same trimer in
complex with the Fab of the CD4bs NAb PGV04. Thus,
one protomer restricts access of the Fab to the CD4bs
on the neighboring protomer [19].
PGT122 showed the opposite preference. Although its
on-rate constants for binding to trimer and protomer
were similar, the off-rate constant was markedly lower
for the trimer than protomer. Therefore the affinity of
the intial interaction (before bivalent strengthening) was
significantly higher for the trimer than the protomer
(Additional file 3: Table S5). This affinity difference might
be explained by the three-dimensional crystallographic
structure of the BG505 SOSIP.664 trimer in complex with
the PGT122 Fab, which shows the intricate relationship of
the PGT122 epitope with the apex of the trimer where the
protomers interact through the V1V2 and V3 variable
regions [18]. Furthermore, it can be noted that intermedi-
ates between germline and mature versions of the bNAbs
PGT121-134 bind better to cell-surface expressed Env
than to monomeric gp120, another indication of a certain
degree of trimer preference for these NAbs [56].
The binding of NAbs to the SOSIP.664 trimer
Binding profiles of IgG versions of NAbs against the trimer
are shown in Figure 4 with the kinetic-modeling results in
Additional file 3: Table S5. A subset of the NAbs were also
studied as Fabs (Additional file 1: Figure S5). The stoicho-
metric estimates for IgGs and Fabs are given in Additional
file 3: Table S4. Notably, the stoichiometric estimates for
the IgGs obtained by the bivalent modeling are given as
the number of paratopes bound per Env molecule (trimer
or protomer). Hence the Sm values for IgG and Fab are
directly comparable (see Additional file 4: Supplementary
results and commentary).
The stoichiometric Sm estimates by SPR for PGV04
IgG and Fab, 1.5 and 1.8, respectively (Additional file 3:
Table S4), fall between those obtained by ITC (1.3) and
EM (average 2.2) with the same trimers. In the EM analysis
of bound PGV04 Fabs, ~44% of the trimer molecules were
occupied by three Fabs, whereas smaller sub-populations
had two, one, or no Fab bound [19]. Causes of the binding
restrictions might be differential glycosylation and glycan
processing. Indeed, when the trimers were deglycosylated
by Endo H, the stoichiometry of PGV04 Fab binding deter-
mined by ITC increased from 1.3 to 2.0 [19].
The Sm estimates for PGT121-3 showed different degrees
of variation among the three methods of deriving them
from the SPR data (1.6-2.8, 1.6-2.5, and 1.9-2.0, respectively;
Additional file 3: Table S4). For comparison, crystallography
has demonstrated that three Fabs of PGT122, which is
similar to PGT121 and PGT123, can bind to the BG505
SOSIP.664 trimer, whereas for PGT121 the stoichiometry
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variations in glycan composition might explain binding
restrictions.
Unlike the other IgGs studied here, 2G12 lacks the
capacity for functionally bivalent binding because of an
unusual domain-swap structure that unites the two inflex-
ible Fab arms into one binding site [57]. Accordingly, its
binding was fitted with the Langmuir model. The Sm value
was 2.9 for the 2G12-trimer interaction (Additional file 3:
Table S4), indicative of nearly complete occupancy and
somewhat higher than the value obtained by ITC, 2.4 [17].
The NAbs PG9, PG16, and PGT145, directed to
broadly similar, quaternary structure-dependent V1V2 gly-
can epitopes, have the unusual maximum stoichiometry of
a single Fab per trimer [16]. By SPR, the stoichiometric
estimate was close to 1 for all three IgG versions (0.97 for
PG9; 0.96 for PG16; and 0.78 for PGT145 by the most
precise method) and somewhat lower for PGT145 Fab,
0.60 (Additional file 3: Table S4). For comparison, the
stoichiometry of PG9 Fab obtained by ITC was 0.8 [17].
Notably, SPR suggested that PG9, PG16, and PGT145
bound to trimers with stoichiometries similar to those
of VRC01 and PGT122 to protomers, which agrees with
established stoichiometries and thereby validates the
estimates [16,18,19,58,59].
PGT151 bound with an estimated stoichiometry of 2
paratopes per trimer (Additional file 3: Table S4), in agree-
ment with the recent EM data on how this new bNAb
recognizes an epitope formed by contributions from
one gp120 monomer and two gp41 subunits [46,47];
the ITC-derived stoichiometric value, 1.3, was somewhat
lower [46].
The kinetic profiles differed widely among the NAbs, also
among those directed to overlapping epitopes (Figure 4
and Additional file 3: Table S5). The on-rate constant of
the monovalent component for the binding to trimer, kon1,
varied 62-fold; the off-rate constant, koff1,v a r i e dm o r e ,
570-fold, whereas the ratio of these two parameters, i.e.,
the dissociation constant, Kd1, varied 380-fold. That the
combined variation was relatively limited reflects a posi-
tive, albeit weak, correlation of the two kinetic constants
(r=0.67, p=0.05). Since the two constants would diverge
during affinity maturation, their correlation suggests im-
munological and chemical impediments that should ideally
be overcome when designing vaccination strategies. We
return to the apparent influence of the most variable
parameter, koff1, below.
A direct comparison of potency in monovalent binding
and virus neutralization was only possible for the small-
subset of NAbs that we studied also as Fabs, but some
findings are noteworthy. The SPR-derived Kd value for
PGV04 Fab (7.7 nM, Additional file 3: Table S3) was
lower than the corresponding Kd value obtained by ITC,
155 nM [19]. Likewise, the Kd1 value for PGT121 IgG
(0.76 nM, Additional file 3: Table S5) was considerably
lower than the ITC-derived value of Kd for its Fab (151
nM [17]). It is uncertain whether these discrepancies for
PGV04 and PGT121 reflect genuine differences in affinity
between binding to tagged immobilized and untagged
solution-phase trimers, or between the intrinsic affinity of
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Figure 3 Comparisons of VRC01 and PGT122 binding to the Env SOSIP.664 trimer and gp120-gp41ECTO protomer. The sensorgrams show
VRC01 (A) and PGT122 (B) IgG binding to BG505 SOSIP.664 trimers (top) and gp120-gp41ECTO protomers (bottom). The colored curves show the
response at various analyte concentrations as indicated to the right. Note that the color code is the same for all diagrams but that the titration
ranges start and end at different concentrations and also differ in the dilution steps. The modeled curves in black (bivalent model) become
visible only when they diverge from the empirical data. The sensorgrams show one of two of replicates. In some experiments the dissociation
phase had to be extended to 20 min to achieve significant values (T > 10) for kd1 (not shown).
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in Additional file 4: Supplementary results and commen-
tary). It should be noted, however, that the IC50 values for
neutralization of the BG505.T332N pseudovirus by the
PGV04 and PGT121 Fabs were 3.5 and 1.1 nM, i.e. close
to the SPR Kd and Kd1 values (Additional file 3: Table S6).
If Fabs have the same affinity for SOSIP.664 trimers as for
functional spikes on virions, the Kd values obtained SPR
would agree with observations and modeling of neutral-
izing occupancies [2,29,50-53]. The ITC values suggest
substantial affinity differences between the soluble and
the virion-anchored native trimers, or else neutralization
potency should be considerably lower. Hence, it will be
important to understand the bases for these measure-
ments to allow optimal mimicry of native trimers.
The Kd for the PGT123 Fab derived by SPR (5.1 nM,
Additional file 3: Table S3) and the corresponding IC50
value (2.1 nM) were also close (Additional file 3: Tables
S3 and S6). 2G12 had a somewhat lower Kd by SPR, 1.3
nM, than its IC50 value (5.1 nM), but as has been noted,
the affinity for the 2G12-affinity-purified trimer is expected
to be higher than for the average native trimer on virions
[17]. For comparison, the Kd for 2G12 obtained by ITC was
16 nM, although a lower-affinity interaction was also
detected with a Kd ~ 12 μM.
The IC50 for PGT145 Fab neutralization of BG505.
T332N pseudovirus, 2.7 nM, was close to the Kd for the
Fab, 2.0 nM (and to Kd1 for monovalent binding of IgG,
2.9 nM); if the measured affinity were relevant, 50%
neutralization and 50% occupancy of Fab on trimer
would approximately coincide (Additional file 3: Tables
S3 and S6). This agrees with modeling of neutralization
data for other HIV-1 strains [50,52].
A greater discrepancy between binding and neutralization
was observed for PGT151 than for the other NAbs. The
Kd1 for the monovalent component of IgG binding to
trimer was 6.3 nM; the Kd for Fab was 7.2 nM, i.e. the
two dissociation constants agreed excellently. In contrast,
the IC50 for IgG was markedly low, 0.010 nM (no Fab
neutralization data were available), lower than would be
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Figure 4 The kinetics of bNAb interactions with SOSIP.664 trimers. The sensorgrams show binding titrations fitted with the bivalent model
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for the other NAbs (Additional file 3: Table S6). Therefore
it is plausible that the truncation at residue 664 and the
stabilizing modifications of BG505 SOSIP.664 render the
affinity of PGT151 for the soluble trimer lower than for
functional spikes on the virion. Thus with the exception
of PGT151, if the SPR conditions simulate binding to
functional trimers, then 50% neutralization would occur
in an approximate zone around 50% occupancy, which
agrees with modeling of neutralization data for other
HIV-1 strains [50,52].
The persistent fraction in neutralization compared with
kinetics and stoichiometry of binding to BG505
SOSIP.664 trimers
What binding properties of NAbs apart from affinity for
functional Env trimers can influence how well they
neutralize? Neutralization is often characterized merely
in terms of potency, i.e. NAb IC50, but the efficacy or
degree of neutralization is also important. Some NAbs,
including PG16 and others to quaternary-structural
epitopes, when used against particular viral isolates,
yield neutralization curves with shallow slopes and low
maximum plateaus [44,61]. But NAbs that give ~100%
neutralization in conventional plots of relative reduction
in infectivity as a function of log NAb concentration can
differ widely in efficacy. Classically, the persistent fraction
(PF) of infectivity at maximum neutralization has been
measured as the logarithmic relative residual infectivity,
which can range over many orders of magnitude. In
contrast, conventional neutralization plots often show
significant effects over less than one order of magnitude,
and to quantify the PF experimentally requires a dynamic
range that some neutralization assays lack. The PF has
been linked to multiple properties of viruses and Abs,
although Burnet originally attributed it mainly to dis-
sociation by NAb [62-65]. Here, we focus on potential
differential determinants of PF among the NAbs, rather
than among properties of the virions, which were con-
stant in these experiments. The NAbs analyzed in this
manner were those for which we had obtained kinetic
and stoichiometric binding data: PGV04, VRC01, 2G12,
PGT121, PGT122, PGT123, PG9, PG16, PGT145, and
PGT151 (Figure 4, Additional file 3: Tables S4 and S5).
We previously reported a strong correlation between
NAb binding to D7324 epitope-tagged BG505 SOSIP.664
trimers in ELISA and neutralizing potency against the
sequence-matched BG505.T332N pseudovirus [17]. In
conventional plots they all displayed ~100% neutralization.
To explore plateaus of residual infectivity we re-analyzed
the same neutralization data by expressing the log of
relative infectivity as a function of the log of the NAb
concentration (Figure 5, Table 1). The resulting curves
for most of the NAbs tended to level off, yielding widely
different PFs that could be extrapolated with high preci-
sion by non-linear regression fitting of a sigmoid function
to the log-log data (Table 1). We emphasize, however, that
the data do not unequivocally demonstrate PFs even
with the best fits. Ideally the assay should have a wider
dynamic range. And an alternative to absolute plateaus
is the possibility that the curves are biphasic with large
slope reductions for the second part. Regardless, the data
show clear deviations from what would be predicted from
homogenous affinities and uniform thresholds of neutra-
lization. For simplicity, we refer to the viral infectivity in
the less effective zone of neutralization as the PF; the effi-
cacy of neutralization is defined as the extrapolated max-
imum degree of inhibition of viral infectivity. Since the
Figure 5 Persistent fractions in neutralization assays. The infectivity
of BG505.T332N pseudovirus was measured on Tzm-bl cells as luciferase
activity (luminescence) after incubation with NAbs. The log [relative
infectivity] is expressed on the y-axis as a function of the log NAb
concentration [nM] on the x-axis. The data are fitted with a sigmoid
function with variable slope and an unconstrained upper plateau; the
lower plateau as a fitted parameter represents the persistent fraction, PF.
Table 1 Neutralizing and binding properties of bNAbs:
stoichiometry, off-rate constant, and persistent
fraction (PF)
NAb Sm koff1 (1/s) Log PF
VRC01 (n=6)
a 1.6 4.7
. 10
−6 −3.7 ±0.80
PGV04 (n= 4) 1.5 <1.0
. 10
−5 −2.5 ±0.17
PGT121 (n=10) 1.7 8.5
. 10
−6 −2.8 ±0.089
PGT122 (n=8) 1.6 3.0
. 10
−6 −3.2 ±0.39
PGT123 (n=8) 2.0 9.5
. 10
−6 −3.1 ±0.14
2G12 (n= 6) 2.9 1.5
. 10
−4 −1.2 ±0.082
PG9 (n=6) 0.97 7.1
. 10
−4 −2.1 ±0.12
PG16 (n=8) 0.96 2.7
. 10
−3 −1.6 ±0.071
PGT145 (n=6) 0.78 6.9
. 10
−4 −1.3 ±0.12
PGT151 (n=6) 1.8 3.5
. 10
−4 −3.0 ±0.086
aThe values in the Table are derived from global non-linear regression fits of
data from n replicate neutralization titrations ± s.e.m. for the logarithmic PF
values. The n values for SPR analyses are given in Additional file 3: Tables S4
and S5, where the Sm and koff1 are included ± s.e.m.
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geneous, it is noteworthy that 2G12 also gave the highest
PF (Figure 5, Table 1). This heterogeneity would be more
pronounced among the unselected Env proteins incorpo-
rated into the pseudovirions than among the 2G12-
affinity-purified trimers [17], as noted above in relation
to the higher IC50 than Kd for 2G12. We therefore ex-
cluded 2G12 from further analyses.
We next tested the correlations of log PF with the
Hill slope, EC50, kon1, koff1, Kd1,k on2, koff2, Kd2, and Sm.
PF correlated positively with koff1 (r = 0.85; p = 0.0037)
and negatively with Sm (r=− 0.73; p = 0.025). The other
parameters gave no marked or significant correlations. To
test how the two parameters complemented each other, we
also explored the correlation between the PF and the sum
of koff1 ranks and inverse Sm ranks (which did not correlate
with each other). The resulting positive correlation was
even stronger and more significant (r=0.89; two-tailed
p=0.0013). Thus, the influences of high off-rates and
low stoichiometries might be reinforcing each other.
To summarize, we found that the faster the NAb dis-
sociated after its initial encounter with the trimer, and
the lower the stoichiometry (excluding 2G12), the higher
was the PF. Dissociation of the NAb, in the dynamic
situation of competition between NAb and receptors for
binding to Env, may leave some persistent infectivity. And
neutralization might be more vulnerable to dissociation
when a single paratope binds to an Env trimer than when
three can bind; for even when three can bind, a single
bound paratope may be sufficient to inactivate the trimer
[2,50,52]. Still, the relationship between stoichiometry and
PF may be a mere coincidence; the real cause might be
the heterogeneity of the epitopes that are affected by
varied glycosylation, including in this case 2G12, which
gave the highest PF.
The observed curve shapes and displacements can be
explained if some degree of bivalent binding occurs with
the pseudovirions; and if, close to saturation, IgG binds
predominantly in a monovalent fashion in accordance
with the well-established prozone effect [66]. At that
high occupancy, inhibition by IgG would approach that
of the Fab. Thereby, if a NAb has a strong capacity for
bivalent binding because of a favorable epitope location,
this will benefit potency more than efficacy.
Conclusions
SPR has been used in multiple formats to study HIV-1
Env-NAb interactions. In some studies, Abs or Fabs have
been captured and the binding of various forms of
gp120 or uncleaved gp140 proteins in solution analyzed.
In other studies, gp120, native-like SOSIP trimers, or
uncleaved gp140s have been covalently immobilized and
Fab or IgG used in solution [11,12,67-70]. Even when
there is potential for more complex binding, simple
Langmuir models have generally been fitted to the binding
data [11,12,67-69]. These approaches have shortcomings.
For example, gp120 monomers and uncleaved gp140s,
which do not mimic functional spikes, have often been
used; Env proteins can be distorted by direct covalent
immobilization to the chips; when trimers are used in
solution, weak interactions can be augmented through
trivalent binding; and Fabs, although excellent tools for
dissecting intrinsic affinity, bind differently from IgGs.
Here, we analyzed IgG and Fab binding to native-like
BG505 SOSIP.664 trimers, which were immobilized via
C-terminal tags so as to impair their antigenicity minimally,
an approach we previously applied in qualitative studies
[17,23]. We dissected the effects of the individual modifica-
tions that were introduced to make a stable, cleaved SOSIP
trimer, compared the trimer with the corresponding
gp120 monomer and gp120-gp41ECTO protomer, mod-
eled the binding kinetics and stoichiometries of a panel
of bNAbs, and related these results to the persistent
fraction of neutralization.
We show that proteolytic cleavage and the stabilizing
modifications all contribute to the native-like antigenic-
ity of the BG505 SOSIP.664 trimer. In many respects,
uncleaved gp140, the gp120-gp41ECTO protomer, and
monomeric gp120 are antigenically similar, in that they
bind non-NAbs strongly but interact weakly or not at all
with bNAbs directed to quaternary structure-dependent
epitopes at the trimer apex.
We identify a variety of kinetic profiles for the binding
of different bNAbs to the native-like trimers, some fea-
turing extremely low koff1 values, at or below the limit of
detection (e.g., VRC01, PGV04, PGT121, PGT122, and
PGT123; Figures 3 and 4; Additional file 1: Figure S5;
Additional file 3: Tables S3 and S5). Of biological im-
portance, such low off-rate constants agree with the slow
genesis of NAbs through multiple rounds of somatic
hypermutation in the germinal centers of lymph nodes
[71-75]. When virus or Env dissociates slowly enough
from B-cell receptors, the rate of internalization of the
complex becomes limiting for antigen presentation to
follicular T-helper cells and thereby for positive selection
of increased affinity. When a new Env mutant arises, the
B-cell receptor adapts through mutations, reducing koff
until the internalization rate again becomes limiting.
Eventually the effects of such iterative selection would
be reflected in the kinetics of NAb binding to heterol-
ogous Env as, for example, studied here.
The kinetic profiles for several of the NAbs we have
analyzed suggest more leeway in increasing kon than in
lowering koff. Only for the PGT145 bNAb did the kon
verge on the diffusion limit (i.e., 10
5-10
6 (1/Ms)) [74,75].
One task in designing immunogens for sequential
immunization is therefore to guide somatic hyper-
mutation towards higher on-rate constants for cross-
Yasmeen et al. Retrovirology 2014, 11:41 Page 11 of 17
http://www.retrovirology.com/content/11/1/41reacting NAbs, perhaps by manipulating bNAb epitope
accessibility [75].
We found that fast dissociation and low stoichiometry
were associated with large PFs. We argue that neutral-
ization by bNAbs should be described not only as potency
but also as efficacy, i.e. the maximum extent of inhibition.
For a high PF may allow infection in vivo, even in the face
of a potent bNAb.
Passive immunization with 2G12 or PGT121 is particu-
larly efficient at preventing mucosal transmission in
the SHIV-macaque model of HIV-1 infection [76,77].
Of course, binding properties of any bNAbs that could
explain why they protect well must be shown to apply
to Env from the challenge virus. Even so, the high stoichi-
ometry and on-rate constant of 2G12 and the extremely
low off-rate constant of PGT121, detected with BG505
SOSIP.664 trimers, are noteworthy.
To understand neutralization, we must measure the
affinity of NAbs against optimal antigenic mimics of
functional Env trimers, spaced similarly to the spikes on
virions. Our current SPR method partly meets those
criteria. Hence, if NAbs with similar affinities turn out
to protect to widely different extents, validly determined
kinetics and stoichiometry of NAb binding might explain
why. The SPR-based measurements we describe here
complement affinity measured by ITC and stoichiometry
determined both by ITC and EM.
For a vaccine to work, its resulting NAb response must
reduce the residual infectivity of the inoculum to such a
low level that the infection aborts. But how relevant the
PF measured in vitro is to protection in vivo will depend
on the design of the neutralization assay. For example,
2G12 neutralizes partly by decelerating entry after viral
attachment to target cells, whereas CD4bs-, V3-, and
MPER-directed NAbs to various extents shorten the
infectious half-life of virions suspended in fluid phase
[78,79]. How long virus and NAb are incubated before
they reach the target cells will affect which mode of
neutralization dominates, and probably how the kinetics
of NAb binding influence the PF. If NAbs, virus, and
cells are all mixed simultaneously, the on-rate constant
might dominate, but the off-rate constant will remain
important in the dynamic competition between NAbs
and receptors, and between productive entry and abortive
pathways [78,80].
NAbs are also being considered for use in therapeutic
passive immunization aiming to control or even clear
chronic HIV-1 infection [4,73,81-83]. When NAbs are
administered directly, those with the most favorable
binding and neutralizing properties could be selected
and combined. Selection criteria might include com-
plementary kinetic profiles and binding properties
maximizing occupancy of NAbs on virus. The latter will
depend on the stoichiometry of the binding of the
individual NAbs, as well as any synergy or cooperativity
among them [84].
Lastly, the kinetics of NAb binding may also inform
immunogen design. The exposure of an epitope is likely to
be reflected in the on-rate constant for the corresponding
NAb. Thus, engineered mutants of native-like trimers that
bind the same NAb with different kinetics, in particular
with distinct on-rates, might be compared as experimental
immunogens in the search for strong inducers of bNAb
responses.
Methods
Design of Env constructs
The BG505 env gene (BG505.W6M.ENV.C2, GenBank
accession numbers ABA61516 and DQ208458) is derived
from a neonatal subtype A HIV-1 founder virus [85].
BG505 SOSIP.664 gp140 was constructed by introducing
several sequence modifications (all numbering is based on
the HxB2 sequence): A501C and T605C, to create a disul-
fide bond between gp120 and gp41ECTO [7]); I559P in
gp41ECTO, to increase trimer stability [13]; REKR (HXB2
Env amino-acid residues 508–511) changed to RRRRRR
(R6) at the cleavage site between gp120 and gp41ECTO,t o
promote proteolytic processing by furin [8]); T332N in
gp120, to allow the binding of bNAbs that depend on
glycan-332 [58]; a stop codon at gp41ECTO residue 664, to
improve trimer solubility and homogeneity [11,86]). The
codon-optimized gene for BG505 SOSIP.664 gp140 was
produced by Genscript (Piscataway, NJ) and cloned into
the vector pPPI4 after digestion with PstI and NotI [7].
Neutralization of the sequence-matched BG505.T332N
pseudovirus, reported elsewhere for IgG [29], was per-
formed here with Fabs in the same Tzm-bl assay.
The same trimers were also engineered to contain His-
or D7324-epitope-tags at the C-terminus of gp41ECTO,b y
inserting the amino-acid sequences GSGSGGSGHHHHH
HHH or GSAPTKAKRRVVQREKR, respectively, between
residue 664 in gp41ECTO and the stop codon [17].
The monomeric BG505 gp120 construct was created
by introducing a stop codon into the SOSIP.664 gp140
gene at residue 512; the cleavage site was reverted to
wild-type (REKR); C501 was reverted to A501; and the
L111A substitution was introduced to prevent gp120
dimerization [45,87]. Furthermore, to allow capture by
antibody D7324, substitutions R500K and G507Q were
introduced into the C5 region. With these changes, the
C-terminal twelve residues of our BG505 gp120 protein
are KAKRRVVQREKR.
T os t u d yt h ee f f e c t so fc l e a v a g ea n dt h eS O S I Pm o d i f i c a -
tions, the BG505 SOSIP.664 gp140, referred to previously
as SOSIP.R6 for simplicity and comparative purposes
[23], was compared with five other previously described
constructs, all six Env proteins containing the D7324-
tag C-terminal to residue 664 [23]. SOS.R6 is fully
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the I559P modification; WT.SEKS has the natural REKR
cleavage site replaced by the non-scissile motif SEKS,b u t
lacks the SOS and I559P changes; SOS.SEKS has the non-
scissile motif, contains the SOS change but lacks I559P;
IP.SEKS has the non-scissile motif, contains the I559P
change but lacks SOS; SOSIP.SEKS has the non-scissile
motif, and contains the SOS and I559P changes. Note that
the four uncleaved Env proteins have designations in
italics. The IP.R6 construct that is fully cleaved, contains
the I559P change but lacks the intermolecular SOS bond;
this construct and WT.R6 were not studied here as their
subunits dissociate [23]. The various Env proteins were all
expressed in HEK293T cells and purified by 2G12-affinity
followed by size-exclusion chromatography (SEC), as
described previously [17]. At the SEC purification stage,
the SOSIP.664 trimers were separated from the monomeric
gp120-gp41ECTO protomers (Additional file 1: Figure S1).
Thus, the protomer is stabilized by the SOS disulfide bond
and also contains the IP change. The trimer and protomer
fractions used were deemed >95% pure.
Antibodies
VRC01 and PGV04 (also named VRC PG04) to the
CD4bs [59,88] were provided by John Mascola (Vaccine
Research Center, NIH); 14e and 19b, both V3-directed
[17,89], by James Robinson (Tulane University); b12 and
b6, both to the CD4bs [90,91]; F240 to cluster I in gp41
[92]; 2G12 to a mannose-dependent epitope [57], PGT121,
PGT122, PGT123, and PGT128, to glycan- and V3-base-
dependent epitopes [43]; and PG9, PG16, and PGT145
to V1V2- and glycan-dependent quaternary-structural
epitopes [16,44] were supplied by The Scripps Research
Institute and the International AIDS Vaccine Initiative’s
reagent repository. PGT151 to a novel epitope spanning
gp120 and gp41ECTO was supplied by The Scripps Research
Institute [46,47]. Fabs of PGV04, PGT123, and PGT145
were expressed and purified as previously described [93];
PGT145 Fab was co-expressed with the tyrosine-sulfating
TPST-1 enzyme. Then, after ion exchange purification,
the fraction with the highest degree of tyrosine sulfation,
as determined by mass spectrogram, was selected [93].
Surface plasmon resonance
All experiments were performed at 25°C on a Biacore
3000 instrument (GE Healthcare). We used three different
methods for immobilizing Env.
In the first method, epitope-tagged Env was captured
by the polyclonal, affinity-purified Ab preparation D7324
(Aalto BioReagents, Dublin, Eire). This method was used
for qualitative comparison of Env constructs (Figures 1
and 2). First, D7324 was covalently coupled to the dextran
on CM5 chips. During coupling and capture steps, the
flow rate was 10 μl/min. The surface of the chip was
activated by injecting NHS and EDC (1:1 [v/v] mixture of
N-hydroxysuccinimide/n-ethyl-N’-(3-diethylaminopropyl)
carbodiimide) for 7 min. D7324, diluted to 50 μg/ml in
immobilization buffer (10 mM sodium acetate pH 4.5),
was injected for 7 min, yielding ~7000 RU. After the Ab
coupling, ethanolamine was injected for 7 min to deacti-
vate the surface. Epitope-tagged Env, diluted in running
buffer to 20 μg/ml, was then captured, giving ligand
immobilization levels, i.e., RL values, of ~500 RU (or ~ 425
RU, i.e., 15% lower for gp120 to achieve equal amounts
(mol) on the surface). Channels with D7324 Ab but no
Env served as controls. Flow rates of 50 μl/min were used
for all Ab binding, in order to minimize mass-transport
limitation. After the binding of each MAb, the surface was
regenerated by a 90-s pulse of 10 mM glycine, pH 2.0, at a
flow rate of 75 μl/min, which allows the coupled D7324 to
be reused with a new batch of Env. Some drift, i.e. dissoci-
ation of ligand from the capturing Ab, occurred. Hence,
even with only marginal experimental error and changes
in drift during a cycle, this process cannot be perfectly
controlled for by 0-analyte subtraction. Thus, for the
qualitative evaluations based on D7324-epitope tagged
constructs, only the background of the control channel
was subtracted, because of the inconstant dissociation of
ligand (drift) inherent to that method. The mean drift was
1.2
. 10
−3 -1 . 3
. 10
−2 (RU/s) for the trimers and 1.0
. 10
−2 -
1.6
. 10
−2 (RU/s) for the monomers in Figures 1 and 2.
This shortcoming necessitated the use of more stable
immobilization methods for modeling the kinetics of
binding, particularly when the MAb-Env dissociation was
extremely slow.
In the second immobilization method, His-tagged
forms of Env were captured on Ni
2+-NTA chips. All Abs
(IgG or Fab) were screened for non-specific binding to
Ni
2+ by comparing Ni
2+-loaded and NTA-only channels.
Several Abs did give high backgrounds and could only
be studied by other approaches. Despite this limitation,
the Ni
2+-based method was used whenever possible,
because it gave the most stable immobilization of Env
thereby promoting high-quality kinetic modeling. This
was particularly so for gp120-gp41ECTO protomers. This
His-tag immobilization was used for full kinetic analysis of
all IgGs and Fabs with no detectable background binding
to Ni
2+-NTA, specifically 2G12 IgG, PGT121 IgG,
PGT122 IgG and Fab, PGT123 Fab, VRC01 IgG and Fab,
and PG16 IgG. After metallic contaminants had been re-
moved by a pulse of EDTA (350 mM) in running buffer
(150 mM NaCl, 10 mM HEPES, pH 7.4 plus 0.005%
Tween20) for 1 min at a flow rate of 30 μl/min, the chip
was loaded with Ni
2+ by injecting NiCl2 at 2.5 mM for
1m i nw i t haf l o wr a t eo f5μl/min, yielding an addition
of ~50 RU. The running buffer was supplemented with
50 μM EDTA to minimize non-specific binding. His-tagged
Env at 10 μg/ml was injected at 5 μl/min for 2–3m i n
Yasmeen et al. Retrovirology 2014, 11:41 Page 13 of 17
http://www.retrovirology.com/content/11/1/41to capture again an amount yielding a signal of ~500
RU (=RL, see Additional file 2: Table S1). The analyte,
whether IgG or Fab, was injected into the Env and control
channels at a flow rate of 50 μl/min at concentrations
titrated down from 0.5 or 1 μM until no significant signal
was obtained. Association was recorded for 300 s and
dissociation for 600 s in standard experiments, but lon-
ger dissociation times (1200 s) were sometimes used in
attempts to quantify very low off-rate constants. After
the binding of each Ab, the NTA-chip surface was
regenerated with a pulse of EDTA (350 mM) for 1 min
at a flow rate of 30 μl/min, followed by 3 washes with
running buffer (containing 50 μME D T A ) .
The third method for immobilizing Env was used for
Abs that bound detectably to Ni
2+. In these cases, His-
tagged trimers were instead captured by an immobilized
anti-His Ab (GE Healthcare), which was coupled to
CM5 chips as for Ab D7324 (see above), to yield ~15000
RU. Abs were then injected at a flow rate of 50 μl/min
at concentrations titrated downwards from 0.5 or 1 μM
until insignificant binding was reached. After each cycle
of Ab binding, we regenerated the anti-His surface by
injecting a single pulse of 10 mM Glycine (pH 1.5) for
60 s at a flow rate of 30 μl/min. This approach, which
immobilizes Env at stabilities intermediate between
Methods 1 and 2 above, was used for PGV04 (both IgG
and Fab), and for IgG versions of PGT123, 2G12, PG9,
PGT145, and PGT151. The 2G12 IgG was also tested by
using the Ni-NTA capture method for cross-validation.
We found substantial background binding for sCD4
with both Ni-NTA and anti-His antibody; while that
background does not preclude the qualitative assessment
of sCD4 binding to SOSIP.664 trimers [17], it precludes
rigorous kinetic analysis. Accordingly, we chose not to
study sCD4 binding by any of the SPR methods here.
In addition to immobilizing Env, we used the untagged
trimer or protomer as analyte. The Abs 14e, 19b, and
PGT145 were captured to~ 550 RU onto the chip by
anti-Fc Ab, immobilized the same way as the D7324 Ab
above, and the binding of untagged BG505 SOSIP.664
trimers or protomers titrated down from 200 nM and at
a flow rate of 50 μl/min was monitored. Association was
recorded for 300 s, dissociation for 600 s.
Evaluation of binding data
For all kinetic modeling, and hence with all data derived
from His-tagged constructs, background values from
control channels, as well as those obtained by injecting
buffer (0 analyte) in the test channel, were subtracted. In
these experiments, the analytes were titrated to allow for
a complete modeling of the kinetics. Other experiments
were performed at single analyte concentrations to assess
differential antigenicity qualitatively.
To minimize the risk of mass-transfer limitation, all
experiments were performed with a flow rate of 50 μl/ml.
Preliminary experiments showed no increase in signal
when the rate was>40 μl/ml. Furthermore, the data were
scrutinized for possible mass-transport limitation by the
following criteria before further modeling: first, the ln(dR/
dt) plots were inspected and found to be approximately
straight with a downward slope in the association phase.
Second, the tentatively best model with a mass-transport
component added was fitted globally to ascertain that the
resulting kt values were>10
8 (RU M
−1 s
−1). These kt
values were typically either just above 10
8 (RU M
−1 s
−1)
with T(kt)>10, or they were >>10
8 (RU M
−1 s
−1)w i t hT
(kt)<10; both outcomes were deemed to be acceptable.
Third, as a further precaution, in the final modeling
(without any mass-transfer component), only fitted pa-
rameters with T> 10 were accepted. It should also be
noted that the majority of the kon values measured
were <10
5 (M
−1 s
−1), i.e. below the risk zone for serious
mass transfer limitations.
Two different kinetic models were applied (as included
in BIAevaluation version 4, GE Healthcare). For IgG
molecules known to be capable of bivalent binding, the
bivalent model yielded variable improvements in fit
over a simple Langmuir model, see Additional file 3:
Table S2). Monovalent analytes (Fabs, 2G12, and trimer
against immobilized PGT145) were fitted with the simple
Langmuir model.
Data on neutralization of BG505.T332N pseudovirus
by IgG NAbs from previous studies [17,47] and in add-
ition by Fabs, obtained by the same method, were con-
verted to logarithmic relative infectivities and modeled
with an unconstrained sigmoid function with a variable
slope, to allow us to identify the persistent fractions, PF
[62-64]. We also determined the Hill slope and IC50 values
by fitting a regular sigmoid function with variable slope
and top and bottom plateaus constrained to 1 and 0,
respectively. Statistical analyses are described in the SI.
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